<DOC>
	<DOCNO>NCT00486304</DOCNO>
	<brief_summary>RATIONALE : Eating diet low antioxidant may control cachexia patient oropharyngeal cancer . PURPOSE : This randomized phase I trial study side effect low antioxidant diet control cachexia patient oropharyngeal cancer receive chemotherapy radiation therapy .</brief_summary>
	<brief_title>Low Antioxidant Diet Controlling Cachexia Patients With Oropharyngeal Cancer Receiving Chemotherapy Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety antioxidant-deficient diet ( ADD ) control cachexia patient oropharyngeal cancer receive chemoradiotherapy . Secondary - Determine safety ADD measure quality life , peripheral DNA damage , change body weight . - Determine effectiveness ADD tumor growth surrogate marker tumor growth . - Determine whether ADD effective improve tumor cachexia syndrome patient . - Determine whether serum metabolomic signature ADD . OUTLINE : This prospective , randomize , double-blind , placebo-controlled study . Patients randomize 1 2 treatment arm . - Arm I : Patients consume standard diet 3 time day 8 week . - Arm II : Patients consume antioxidant-deficient diet ( ADD ) 3 time day 8 week . Patients receive replacement vitamin week 9 . All patient receive plan chemoradiotherapy week 3-8 . Quality life , body composition ( dual-energy x-ray absorptiometry ) , weight , rest energy expenditure ( indirect calorimetry ) assess baseline week 8 . Blood sample collect baseline 8 week . Samples evaluate cytokine level ; evidence DNA damage peripheral blood lymphocyte ; serum signature characteristic ADD multinuclear MRI spectroscopy . Patients undergo tumor biopsy week 4 research study . Samples collect evaluated generation reactive oxygen specie use antibody oxidatively modify DNA lipid ; apoptosis use TdT-mediated dUTP nick-end label assay classical morphological criterion ; level tumor toxohormones lipid mobilize factor proteolysis induce factor real time-PCR , northern blotting , western blot method . After completion study therapy , patient follow week 9-12 .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Body Weight Changes</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven carcinoma oropharynx ( regardless primary diagnosis recurrence ) No active treatment disease within past 4 week PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Feeding tube allow Prior malignancy allow provide follow criterion meet : Patient undergone potentially curative therapy prior malignancy There evidence prior malignancy within past 5 year ( except successfully treat cervical nonmelanoma skin cancer evidence recurrence ) Patient deem treat physician low risk recurrence prior malignancy Must able speak English Must adequate home refrigeration No intractable vomit No ascites clinical/ultrasound evidence fluid retention No uncontrolled hypertension No severe congestive heart failure No pneumonia No severe infection No know HIV positivity No coexist medical condition would preclude study compliance No decisionallyimpaired individual No history abetalipoproteinemia ( BassenKornzweig syndrome ) No history spinocerebellar ataxia No history chronic cholestatic hepatobiliary disease No history diagnose vitamin E deficiency No history proteinenergy malnutrition ( marasmus kwashiorkor ) No history disorder relate malabsorption ( e.g. , celiac disease , sprue , cystic fibrosis , duodenal bypass , congenital partial obstruction jejunum , obstruction bile duct , giardiasis , cirrhosis ) No history achlorhydria PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent parenteral nutrition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>cachexia</keyword>
	<keyword>weight change</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
	<keyword>stage I oropharyngeal cancer</keyword>
	<keyword>stage II oropharyngeal cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
</DOC>